Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Tauritmo 25mg Capsule:
Tauritmo 25mg Capsule contains the active ingredient Midostaurin and is classified as a chemotherapy medication. It is specifically indicated for the treatment of adults diagnosed with acute myeloid leukemia (AML) associated with a genetic mutation called FLT3, as well as for certain types of mastocytosis characterized by excessive production of mast cells.
Mechanism of Action of Tauritmo 25mg Capsule:
Tauritmo 25mg Capsule functions by targeting and inhibiting the activity of enzymes known as receptor tyrosine kinases within cancer cells. By disrupting the signaling pathways of growth factor receptors, stem cells, and tyrosine kinase enzymes, it effectively impedes the growth and spread of cancer cells.
Uses of Tauritmo 25mg Capsule:
Tauritmo 25mg Capsule is indicated for the treatment of the following conditions:
Newly diagnosed Acute Myeloid Leukemia (AML), used in combination with other chemotherapy medications.
Aggressive systemic mastocytosis.
Mast cell leukemia.
Systemic mastocytosis with associated hematological neoplasm.
Dosage and Administration:
The dosage and administration of Tauritmo 25mg Capsule should be determined by a healthcare professional based on individual patient factors and response to treatment. It is important to follow the prescribed regimen diligently to achieve optimal therapeutic outcomes.
Side Effects:
Common side effects of Tauritmo 25mg Capsule may include headaches, gastrointestinal disturbances, and nausea. Regular monitoring and management of side effects are essential during the course of treatment.